TVGN - NASDAQ
Tevogen Bio Holdings Inc.
$0.25
-5.8%Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
At a Glance
Live SnapshotTevogen Bio Holdings Inc. Management Team
Mr. Sadiq Khan M.B.A.
Chief Commercial Officer
Mr. Kirti Desai CPA
Chief Financial Officer
Compensation
$300,000
Mr. Mittul Mehta
Chief Information Officer & Head of Tevogen.ai
Dr. Neal Flomenberg M.D.
Chief Scientific Officer and Global R&D Lead
Compensation
$350,000
Mr. Stephen Chen M.B.A.
Chief Technical Officer
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.
Co-Founder, Chief Executive Officer & Chairperson
Compensation
$501,000
Mr. David E. Banko CPA
Global Head of Government Affairs & Patient Access
Mr. Tapan V. Shah
Head of Investor Relations & Corporate Development
Tevogen Bio Holdings Inc. Insider Positioning
During the last 12 months, insiders have sold $1.77M worth of TVGN shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
1.4M
1.77M
-1.8M
-$1.77M
Top Buyers
No buying activity
Top Sellers
Saadi Ryan H.
Director, 10 Percent Owner, Officer: Chief Executive Officer
$1.77M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.77M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
TVGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | January 26, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | April 30, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | December 04, 2023 | December 04, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | January 20, 2023 | February 03, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.